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Abstract 37	
	38	
Influenza A viruses (IAV) are known to modulate and “hijack” several cellular host 39	
mechanisms, including gene splicing and RNA maturation machineries. These modulations 40	
alter host cellular responses and enable an optimal expression of viral products throughout 41	
infection. The interplay between the host protein p53 and IAV, in particular through the viral 42	
nonstructural protein NS1, has been shown to be supportive for IAV replication. However, it 43	
remains unknown whether alternatively spliced isoforms of p53, known to modulate p53 44	
transcriptional activity, are affected by IAV infection and contribute in IAV replication. Using 45	
a TP53 minigene, which mimics intron 9 alternative splicing, we have shown here that the NS1 46	
protein of IAV changes the expression pattern of p53 isoforms. Our results demonstrated that 47	
CPSF4 (cellular protein cleavage and polyadenylation specificity factor 4) independently and 48	
the interaction between NS1 and CPSF4 modulate the alternative splicing of TP53 transcripts 49	
which may result in the differential activation of p53 responsive genes. Finally, we reported 50	
that CPSF4 and most likely beta and gamma spliced p53 isoforms affect both viral replication 51	
and IAV-associated type I interferon secretion. Altogether, our data showed that cellular p53 52	
and CPSF4 factors, both interacting with viral NS1, have a crucial role during IAV replication 53	
that allows IAV to interact and alter the expression of alternatively spliced p53 isoforms in 54	
order to regulate the cellular innate response, especially via type I interferon secretion, and 55	
perform efficient viral replication.   56	
	 3	
Importance 57	
	58	
Influenza A viruses (IAV) constitute a major public health issue, causing illness and death in 59	
high-risk populations during seasonal epidemics or pandemics. IAV are known to modulate 60	
cellular pathways to promote their replication and avoid immune restriction via the targeting of 61	
several cellular proteins. One of these proteins, p53, is a master regulator involved in a large 62	
panel of biological processes, including cell cycle arrest, apoptosis or senescence. This “cellular 63	
gatekeeper” is also involved in the control of viral infections, and viruses have developed a 64	
wide diversity of mechanisms to modulate/hijack p53 functions to achieve an optimal 65	
replication in their hosts. Our group and others have previously shown that p53 activity was 66	
finely modulated by different multi-level mechanisms during IAV infection. Here, we 67	
characterized IAV non-structural protein NS1 and the cellular factor CPSF4 as major partners 68	
involved in the IAV-induced modulation of the TP53 alternative splicing that was associated 69	
with a strong modulation of p53 activity and notably the p53-mediated antiviral response.  70	
 	  71	
	 4	
Introduction 72	
 73	
Influenza A viruses (IAV) constitute a major public health issue, causing illness and death in 74	
high-risk populations during seasonal epidemics or pandemics (1, 2). IAV belong to the family 75	
Orthomyxoviridae of enveloped viruses and contain a segmented genome of single-stranded 76	
negative-sense RNA (3). In contrast to most RNA viruses, IAV have a nuclear infectious cycle, 77	
therefore requiring direct access to numerous nuclear host factors and machineries to 78	
successfully achieve their replication (4). These viruses have notably developed mechanisms to 79	
reassign the host spliceosome to simultaneously alter host cellular expression and enable an 80	
optimal expression of specific spliced viral products throughout infection (reviewed in (5)). 81	
Although the regulation of viral splicing has been extensively studied, the intricate interactions 82	
between IAV and the host spliceosome, as well as the host splicing regulators, remain to be 83	
further deciphered. 84	
Among IAV proteins, the non-structural NS1 is known to be a key “multi-tool” protein with 85	
which the virus can extensively alter the host-cell responses (6-9). Indeed, NS1 can counteract 86	
the antiviral interferon (IFN) response using several mechanisms (6-8). In particular, NS1 acts 87	
as a modulator of numerous cellular host processes, including mRNA processing (5, 10), 88	
nuclear trafficking/export (11, 12) and translation (13, 14). These multiple accessory functions 89	
are well illustrated by the considerable number of NS1 host interactors (more than 50) and the 90	
numerous binding sites within the NS1 protein, which include for example binding sites for 91	
double-stranded RNA (15, 16), p85β for activation of phosphatidylinositol-3-kinase (PI3K) 92	
signaling (17), RIG-I, which inhibits the induction of the type I IFN response (IFN-I) (18-20), 93	
and cleavage and polyadenylation specificity factor 4 (CPSF4; also known as CPSF30) (21). 94	
Among the NS1-interacting host proteins, CPSF4 is a component of the CPSF complex, which 95	
is involved in the last step of mRNA maturation and polyadenylation (22, 23). It has been 96	
demonstrated that IAV NS1 interacts with CPSF4, thus preventing CPSF4 binding to RNA and, 97	
consequently, inhibiting the 3′ end cleavage and polyadenylation of host pre-mRNA (21). It is 98	
assumed that this interaction contributes to the NS1-dependent regulation of several host genes 99	
and particularly to the inhibition of the IFN-response (24-27). Furthermore, it has been recently 100	
suggested that the CPSF complex could promote alternative splicing events. The CPSF complex 101	
can be recruited as a cofactor by known splicing regulators at sites distal to the polyadenylation 102	
site simultaneously to its usual mRNA binding sites (28-30). These data suggest that the 103	
interaction between NS1 and CPSF4 could also affect host gene expression at another level of 104	
regulation, such as host mRNA splicing. 105	
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The host tumor suppressor p53 is a master regulatory transcription factor that is activated in 106	
response to various cellular stresses and that regulates a broad range of biological processes, 107	
such as cell-cycle arrest, apoptosis and senescence (31, 32). An increasing number of reports 108	
suggest that p53 is also a key player in the regulation of immune, inflammatory and antiviral 109	
responses, including that of influenza viruses (33-42). Our current understanding is that the 110	
IAV-induced modulation of p53 endogenous expression, and subsequently of p53 111	
transcriptional activity, contributes to maintain a cellular state that favors viral replication 112	
during the time of infection (41, 43). We and others have indeed demonstrated that NS1 plays 113	
a major role in the functional interplay between IAV and the host p53 pathway (37, 42). We 114	
have shown that NS1 interacts with the endogenous p53 protein and alters the binding of p53 115	
to its responsive genes in a promoter-dependent manner (37). However, the complete 116	
mechanisms of NS1-induced modulation of p53 activity are still not fully understood. In 117	
addition to the canonical full-length p53 protein (also called TAp53a or p53α), the TP53 gene 118	
expresses about twelve p53 protein isoforms that result from combinational use of alternative 119	
promoters, splicing sites and/or translational initiation sites (44, 45). In particular, three C-120	
terminal variants have been described (a, b and g) that result from alternative splicing of TP53 121	
intron 9 (TP53-i9). Exclusion of the entire intron 9 generates the canonical full-length p53 122	
protein (or p53a), whereas inclusion of alternative exons 9b and 9g contained in intron 9 gives 123	
rise to p53b and p53g protein isoforms that present short residue sequence in place of the usual 124	
oligomerization domain present in p53a, resulting in shorter forms (47 kDa instead of 53 kDa) 125	
(44, 45). 126	
The p53 isoforms have been shown to contribute to the cell-fate decision in response to stress 127	
but also to the maintenance of cell homeostasis, mainly by regulating transcriptional activity of 128	
the full-length p53a protein (44, 46, 47). We have notably demonstrated that increased 129	
expression of the C-terminal p53β and p53γ isoforms, resulting from fine control of the 130	
alternative splicing of TP53-i9, promotes G1 cell-cycle arrest and apoptosis in a p53a-131	
dependent manner (47). Interestingly, we reported that IAV differentially affect the endogenous 132	
expression of p53 isoforms at both transcriptional and post-transcriptional levels. In response 133	
to influenza infection, we observed an increased expression of the p53b isoform, known to be 134	
generated by partial retention of TP53-i9 (46). Reciprocally, modulations of endogenous 135	
expression of p53 isoforms affect viral replication in a p53a-dependent manner (38). 136	
Here, we further characterized the functional connections between IAV and the host p53 137	
pathway at the level of C-terminal spliced p53 isoforms. Using a minigene construct, we 138	
	 6	
demonstrated that TP53 splicing is strongly modulated during the time course of IAV infection. 139	
In addition, we characterized the viral protein NS1 and the host factor CPSF4 as major partners 140	
involved in the IAV-induced modulation of the TP53 alternative splicing that was associated 141	
with a strong modulation of p53 transcriptional activity. Our study highlights for the first time 142	
a role for a cell factor, CPSF4, in TP53 alternative splicing in response to viral infection, and 143	
we have identified a novel regulator of TP53 alternative splicing in basal conditions. In the 144	
context of IAV infection, our results suggest that not only spliced p53β and p53γ isoforms, but 145	
also CPSF4, may contribute to the p53-mediated antiviral type I IFN response.    146	
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Results 147	
	148	
Influenza viral infection and NS1 protein modulates the alternative splicing of TP53-i9.  149	
To investigate the impact of infection on the alternative splicing of TP53-i9, we used a 150	
previously described minigene approach (38). This TP53-i9 minigene mimics alternative 151	
splicing of TP53-i9 and allows the analysis of the exclusion and/or partial retention of intron 9, 152	
which leads to the production of C-terminal a, b or g variants, respectively (Fig. 1A). H1299 153	
p53-null cells were transfected with TP53-i9 minigene plasmids for 36 hours then infected with 154	
two IAV strains (A/Puerto Rico/8/34 (H1N1) or A/Moscow/10/99 (H3N2)) at a multiplicity of 155	
infection (MOI) of 4 or 0.1 for 8 or 24 hours post-infection (hpi), respectively. IAV infection 156	
was validated by monitoring expression of NP and NS1 proteins by western blot, reflecting 157	
only slight differences of viral kinetics (Fig. 1B). Relative spliced RNA levels of the exogenous 158	
a, b and g isoforms of p53, reflecting the three C-terminal spliced variants, were then quantified 159	
by reverse transcription-qPCR (RT-qPCR). Both H1N1 and H3N2 infections affected the levels 160	
of a, b and g p53 isoforms compared with mock-infected cells (Fig. 1B). At 8 hpi (MOI of 4), 161	
we observed a significant increase of the p53γ isoform levels by 1.39 and 1.27-fold in cells 162	
infected by H1N1 and H3N2, respectively, compared with the mock infection. However, no 163	
significant change was observed for both the α and β isoforms. In the context of multiple viral 164	
cycles (that is, MOI of 0.1 and 24 hpi), we observed a broader effect of infection on retention 165	
of TP53-i9. In addition to a significant 1.44- and 1.36-fold increase in the level of the p53γ 166	
isoform for H1N1 and H3N2, respectively, the level of the β isoform was also significantly 167	
increased in IAV-infected cells compared with mock-infected cells (1.43- and 1.60-fold 168	
increase for H1N1 and H3N2, respectively) (Fig. 1B). By contrast, the level of the major α 169	
isoform remained unaffected by H3N2 infection or slightly decreased by H1N1 infection. These 170	
results suggest that IAV infection promotes the retention of TP53-i9, leading to the generation 171	
of b and g variants of p53 and, thus, could explain the IAV-induced expression of the p53b 172	
isoform previously described (38).  173	
As the multifunctional NS1 protein is known to affect the host splicing machinery, we then 174	
investigated whether NS1 could modulate, by itself, the retention of TP53-i9. The TP53-i9 175	
minigene plasmid was co-transfected with the wild-type (wt) NS1-expressing pCI plasmid 176	
(H3N2), which induces NS1 expression, as verified by western blot (Fig. 1C, bottom panel). 177	
RT-qPCR analyses revealed that NS1 affected retention of TP53-i9. Indeed, NS1 expression 178	
was associated with a significant increase of both p53β and γ isoform levels compared with the 179	
empty-plasmid transfection condition, the mean fold increases reaching 3.40 and 2.24, 180	
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respectively (Fig. 1C, top panel). Similar to that observed in the above context of IAV infection, 181	
the level of p53α isoforms remained unaffected by transient NS1 expression. As the β and γ 182	
variants are known to be expressed at lower levels than the major α variant in basal conditions 183	
(36), we also determined the percentage of the combined β and γ (β+γ) isoforms out of the three 184	
C-terminal p53 isoforms to determine the relative proportion of intron 9 retention. NS1 185	
expression induced a significant >2-fold increase of the β+γ isoform proportion compared with 186	
the empty-plasmid condition (14.42 % versus 6.06 %, respectively, Fig. 1C, bottom panel). 187	
Overall, these results indicate that IAV infection, and also NS1 alone, can modulate the 188	
alternative splicing of TP53-i9, and favors the generation of β and γ isoforms of p53.  189	
 190	
The CPSF4-binding domain of NS1 is critical to NS1-mediated modulation of TP53-i9 191	
retention. 192	
The impact of different previously described NS1 mutants (16, 17, 21) on TP53-i9 retention 193	
was assessed using a TP53-i9 minigene in H1299 p53-null cells to determine the mechanisms 194	
underlying NS1-induced retention of TP53-i9. Three pCI plasmids were used to express H3N2 195	
NS1 mutants that are deficient in their binding with either the PI3K p85β subunit (NS1-Y89F), 196	
RNA (NS1-R38A/K41A) or CPSF4 (NS1-CPSF4b), all of which had detectable amount of the 197	
various NS1 proteins (Fig. 1D). Similar to wt NS1, there was a strong and significant 2-fold 198	
increase in the proportion of β+γ isoforms in NS1-Y89F or NS1-R38A/K41A mutants 199	
expressing cells, compared with the empty-plasmid condition, (13.03 and 12.58 % versus 5%, 200	
respectively) (Fig. 1D and Supplementary Fig. 1A). These results suggest that both RNA-201	
binding and p85β-binding domains of NS1 are not involved in the NS1-induced retention of 202	
TP53-i9. By contrast, the increased b+g proportion observed in response to wt NS1 expression 203	
is abrogated when the NS1-CPSF4b mutant was expressed (Fig. 1D), which suggests that NS1 204	
mutants that could not bind to CPSF4 lost the capacity to induce TP53-i9 retention. Of note, 205	
the relative RNA levels of α, β and γ forms generated by the TP53-i9 minigene were 206	
significantly lower in NS1-CPSF4b expressing cells compared with the empty-plasmid 207	
condition, indicating an addition layer of regulation  (Supplementary Fig. 1A).  208	
Increasing numbers of wt NS1 and NS1-CPSF4b-expressing plasmids were then co-transfected 209	
with TP53-i9 minigene in H1299 cells. In the wt NS1 condition, no dose-dependent effect was 210	
observed, and even minimal quantities of wt NS1 plasmid — resulting in a barely detectable 211	
protein levels — were sufficient to significantly increase the exogenous b+g isoform proportion 212	
(Fig 1E and Supplementary Fig. 1B). By contrast, the generation of α, b and g forms from the 213	
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TP53-i9 minigene was progressively reduced with the NS1-CPSF4b mutant as the introduced 214	
plasmid quantity increased (Supplementary Fig. 1B). The augmentation of the b+g isoform 215	
proportion was abrogated at each NS1-CPSF4b dose used, which suggests that the CPSF4-216	
binding domain of NS1 has a role in regulating TP53-i9 retention (Fig. 1E). At endogenous 217	
levels in A549 cells expressing the wt TP53 gene, we observed concordant patterns of p53β 218	
protein augmentation with wt NS1 versus its absence with NS1-CPSF4b, at least when low 219	
amounts of plasmid were transfected (Supplementary Fig.1D), in accordance with previous 220	
results (38). Altogether, these results suggest that the CPSF4-binding domain of NS1 is critical 221	
for the NS1-induced retention of TP53-i9. 222	
 223	
 224	
IAV-mediated regulation of p53 expression is affected in NS1 CPSF4-mutant influenza 225	
virus. 226	
We then investigated the impact of NS1-CPSF4b on the expression of spliced p53 isoforms in 227	
the context of IAV infection. The NS1-CPSF4b mutant virus was previously described as 228	
having strongly attenuated replication (48). To minimize this limitation, we used the reverse 229	
genetic system of the highly replicative A/PuertoRico/8/33 virus (H1N1, PR8) (49) to produce 230	
viruses expressing the wt NS1 or mutant NS1-CPSF4b proteins. Virus recovery from pHW2000 231	
plasmid transfection was achieved, and recombinant PR8/NS1-wt and PR8/NS1-CPSF4b 232	
viruses were generated and titrated. These two viruses presented comparable growth kinetics 233	
and infectivity (Fig. 2A). A549 cells (p53 wt) were infected with either virus, and endogenous 234	
mRNA relative levels of p53 isoforms were measured by RT-qPCR and western blot. At 8 hpi, 235	
the PR8/NS1-wt virus induced a significant 25% reduction of endogenous p53 total mRNA 236	
levels compared with mock infection, and a slight but not significant increase in both p53b 237	
isoform mRNA and protein levels (Fig. 2B, C). Thus, infection with PR8/NS1-wt virus 238	
reproduced what was observed with endogenous p53 isoform at mRNA and protein levels (38) 239	
and in H1299 NS1-transfected cells (Fig. 1C). In contrast to PR8/NS1-wt virus, no variation of 240	
total p53 mRNA levels was observed with PR8/NS1-CPSF4b virus at 8 hpi compared with 241	
mock infection, while a significant 1.65-fold up-regulation of β mRNA variants and a slight 242	
increase of p53β protein levels was detected, suggesting that the CPSF4-binding domain of NS1 243	
has a role in modulating p53 isoform expression (Fig. 2B,C). At 24 hpi, no changes were 244	
observed at mRNA levels in the PR8/NS1-wt virus-infected cells, whereas a drastic and 245	
significant increase of β mRNA variants was induced by PR8/NS1-CPSF4b infection compared 246	
with mock infection (Fig. 2D). However, this increase of mRNA levels was not matched by a 247	
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similar increase in p53β protein levels, as observed by western blot (Fig. 2E). This discrepancy 248	
can result from other regulations occurring during the several viral cycles taking place through 249	
the time course of 24 hpi. Nevertheless, these data showed that endogenous p53 isoforms 250	
expression is differentially affected by influenza virus expressing either the wt NS1 or NS1-251	
CPSF4b mutant protein, underlying the critical role of the CPSF4 binding domain in NS1-252	
induced modulation of p53 isoform expression.  253	
Interestingly, we observed that CPSF4 itself affects spliced p53 isoforms expression in basal 254	
conditions. In fact, we observed a slight increase of α variant mRNA in conjunction with a 255	
significant 40% reduction of b variant mRNA levels in p53-null H1299 cells, previously 256	
transfected with the TP53-i9 minigene plasmid, when treated with a pool of small interfering 257	
RNA that targeted CPSF4 (si-CPSF4), in comparison with a non-specific si-RNA (si-ctrl) 258	
(Supplementary Fig. 2A). In accordance, a similar observation was made at endogenous levels 259	
in si-CPSF4-treated A549 cells with an increase in total p53 mRNA levels but no change in the 260	
proportion of β variant mRNA levels when compared with si-ctrl treated cells (Supplementary 261	
Fig. 2B). Thus, these results suggest that the silencing of the cellular CPSF4 factor contributes 262	
to the exclusion of TP53-i9, which modulates the spliced p53 isoforms ratio and favors the 263	
increase of p53a variant mRNA levels — the major form expressed by the TP53 gene. 264	
Altogether, these results demonstrated that CPSF4-binding domain of NS1 is critical for the 265	
IAV-mediated regulation of p53 isoforms expression. Moreover, it suggests a role of the NS1 266	
interactant, CPSF4, in p53 isoform expression in both mock and infected conditions. 267	
 268	
CPSF4, NS1 and the CPSF4-binding domain of NS1 protein play a critical role in p53 269	
transcriptional activity. 270	
As we observed that silencing of CPSF4 modulates p53 isoforms expression patterns in basal 271	
conditions, we investigated the effect of CPSF4 silencing on p53 transcriptional activity in non-272	
infected cells. We used a panel of luciferase reporter vectors that reflect either the intrinsic p53 273	
transcriptional activity (pG13-Luc, a de novo generated promoter containing 13 consecutive 274	
p53 responsive elements) or promoter activity of well-characterized p53 target genes (MDM2-275	
Luc, p21-Luc or Bax-Luc). Compared with si-ctrl, si-CPSF4 treatment increased pGL13-Luc 276	
luciferase activity, indicating that CPSF4 modulates p53 transcriptional activity 277	
(Supplementary Fig. 2C). These results support that CPSF4 contributes to modulate the 278	
transcriptional activity of p53 in a promoter-dependent manner. 279	
We then investigated whether the NS1-mediated modulation of p53 isoforms expression pattern 280	
affected p53 transcriptional activity and whether such modulation was dependent on the 281	
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CPSF4-binding domain of NS1 (Fig. 3). Increasing amounts of wt NS1- or NS1-CPSF4-282	
expressing vectors were co-transfected with either a pG13-Luc, MDM2-Luc, p21-Luc or Bax-283	
Luc luciferase reporter vector in A549 cells (NS1 expression was verified by western blot in 284	
Supplementary Fig. 1C). In wt H3N2 NS1 transfected cells, we observed a slight decrease of 285	
the pG13-Luc luciferase activity together with significant increase of Bax and reduction of 286	
MDM2 and p21 promoter activities compared with the empty-plasmid condition, which 287	
suggests that NS1 modulates p53 transcriptional activity (Fig. 3), in accordance with previously 288	
published studies (including ours), demonstrating that NS1 modulates p53 transcriptional 289	
activity in a promoter-specific manner (37, 42). In cells expressing the NS1-CPSF4b mutant, 290	
pG13-Luc luciferase activity was significantly increased compared with the control and wt NS1 291	
conditions, resulting in dose-dependent increase of relative luciferase activity reaching a 292	
maximum of 6-fold induction. This was supported by the observations that NS1-CPSF4b 293	
mutant differentially affected MDM2-Luc, p21-Luc and Bax-Luc promoter activities compared 294	
with wt NS1 (Fig 3). These results indicate that the CPFS4-binding domain of NS1 plays a 295	
critical role in the regulation of p53 transcriptional activity.  296	
Altogether, these data indicate that the CPSF4-binding domain of NS1, and CPSF4 itself, 297	
affects p53 transcriptional activity and p53-responsive promoters. In addition, the modulation 298	
of p53 isoform expression pattern, resulting from alternative splicing of TP53-i9 and induced 299	
by NS1 through its CPSF4-binding domain or by CPSF4 itself, was paralleled with modulation 300	
of p53 transcriptional activity, suggesting a functional impact on viral replication.  301	
 302	
The silencing of spliced p53 isoforms impairs IAV replication. 303	
To support the hypothesis of an interplay between NS1, CPSF4 and p53 activity and its 304	
functional impact on viral replication, we first determined whether a combined endogenous 305	
silencing of the TP53-i9 alternatively spliced p53β and γ isoforms could affect IAV replication. 306	
We treated A549 cells with either a si-ctrl or a siRNA that targets alternatively spliced TP53-307	
i9 (si-P53i9) prior infection with H3N2 influenza virus (Fig. 4A). First, we verified the 308	
silencing of spliced p53 isoforms in response to si-P53i9 treatment (Fig. 4C-D). In non-infected 309	
cells, si-P53i9 treatment decreased both b mRNA variant and p53b protein levels by about 40%. 310	
As previously described (28), infection alone (si-ctrl condition) did not affect endogenous p53 311	
total mRNA levels but induced a significant and strong increase in endogenous β mRNA variant 312	
levels at 72 hpi (a 4.23- and 6.80-fold increase compared with mock infections for MOIs of 0.1 313	
and 0.01, respectively) (Fig. 4C). Such induction was abrogated in si-P53i9-treated cells, 314	
demonstrating the si-RNA treatment efficacy along the infection time-course. Second, we 315	
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analyzed IAV cell titers in these conditions (Fig. 4B). Silencing of TP53-i9 spliced p53 316	
isoforms was associated with a significant decrease in viral titers, particularly at 48 hpi with a 317	
6.5- and 19-fold decreased production of influenza virus (for MOIs of 0.1 and 0.01, 318	
respectively) compared with si-ctrl treatment. Accordingly, viral expression of NP and NS1 319	
proteins decreased in si-P53i9-treated cells compared with si-ctrl at 72 hpi, suggesting that 320	
spliced p53 isoforms have pro-viral activity (Fig. 4D). These data are in accordance with our 321	
previously published study, which highlighted p53β as a pro-viral factor (38). 322	
Interestingly, levels of p53α protein were reduced in IAV-infected cells compared with mock-323	
infected cells (si-ctrl condition) at both 48 and 72 hpi (Fig. 4D). Surprisingly, while si-P53i9 324	
treatment did not change the level of p53α protein in mock-infected cells, we clearly observed 325	
more p53α in infected cells and si-P53i9-treated A549 cells compared with si-ctrl-treated cells. 326	
As these variations at the protein level were not observed at the mRNA level, these observations 327	
suggest that C-terminal spliced p53 isoforms contribute to the IAV-reduction of p53a 328	
regulation through a post-transcriptional mechanism (Fig. 4D).  329	
As CPSF4 affects the spliced p53 isoform expression pattern and p53 transcriptional activity 330	
(Supplementary Fig. 2) and as the CPSF4 promoter contains p53-response elements (data not 331	
shown), we analyzed CPSF4 expression in si-P53i9-treated conditions. Interestingly, silencing 332	
of the spliced β and γ mRNA variants was associated with an increase in CPSF4 protein, both 333	
in non-infected and infected conditions, while it decreased CPSF4 mRNA levels, suggesting 334	
there is a regulation of CPSF4 at the transcriptional level and that the CPSF4 protein 335	
stabilization in IAV-infected cells is dependent upon spliced p53 isoforms (Fig. 4D and 336	
Supplementary Fig. 3). These data suggest a regulatory loop between CPSF4 and p53 isoforms 337	
that could modulate IAV infection. 338	
 339	
Silencing of CPSF4 also impacts the IAV replication. 340	
Owing to the multilayer interplay between p53 isoforms and CPSF4, as well as between NS1 341	
and CPSF4, we investigated the impact of cellular CPSF4 silencing on IAV replication. First, 342	
we compared IAV growth kinetics in A549 cells treated with si-CPSF4 or si-ctrl (Fig. 5A). 343	
When CPSF4 expression was drastically reduced by si-CPSF4 treatment, at mRNA and protein 344	
levels (Fig 5B, C), a significant increase of viral replication was observed compared with si-345	
ctrl cells, with viral titers increased by up to 7 times at 72 hpi (MOI of 0.01) (Fig. 5A). 346	
Accordingly, viral expression of NP and NS1 proteins were increased in si-CPSF4-treated cells 347	
compared with si-ctrl-treated cells (Fig. 5B). These data suggest that CPSF4 exhibits an anti-348	
viral effect in an independent manner. Inversely, influenza virus (si-ctrl condition) decreased 349	
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CPSF4 protein expression in A549 cells while it increased CPSF4 mRNA levels, suggesting 350	
there is a regulation of CPSF4 at post-transcriptional levels in response to infection (Fig. 4D 351	
and Supplementary Fig. 3). Moreover, as expected regarding our previous results, si-CPSF4 352	
treatment altered endogenous p53 expression by enhancing levels of both p53α and p53β 353	
proteins at 72 hpi (Fig. 5B).  354	
Second, we measured IAV growth kinetics in H1299 p53-null cells treated with si-CPSF4 or 355	
si-ctrl (Fig. 5D). In clear contrast with results obtained in A549 cells, the si-CPSF4 treatment 356	
had no significant impact on viral growth and very limited impact on viral expression (Fig. 5E). 357	
Interestingly, the increased CPSF4 mRNA levels seen in response to infection in A549 cells 358	
(Fig. 5C) was inhibited in absence of endogenous p53 expression (si-ctrl conditions) (Fig. 5F). 359	
However, at the protein level, CPSF4 protein expression remained elevated in p53-null cells in 360	
both non-infected and infected cells, suggesting that CPSF4 protein stability is dependent upon 361	
p53 (Fig. 5E). These results support a regulatory loop between CPSF4 and p53 during IAV 362	
infection and suggest that the CPSF4 anti-viral effect on IAV replication is p53- dependent. 363	
 364	
TP53 spliced p53β and p53γ isoforms together with CPSF4 contribute to a p53-mediated 365	
type I IFN-response to IAV infection and extracellular stresses. 366	
Given that p53 is a key player in the regulation of innate immune responses (reviewed in (33)), 367	
and that the CPSF4-binding domain of NS1 has been recently associated with the type I IFN 368	
regulation mechanism during infection (50), we wanted to further investigate the role of TP53 369	
gene pathway, as well as that of CPSF4, on type I IFN responses in the context of infection, 370	
using a siRNA-based approach (Fig. 6). A549 cells were transfected with either a pool of 371	
siRNA targeting all p53 isoforms (si-P53tot) (Fig. 4A), siRNA targeting spliced p53β and p53γ 372	
isoforms (si-P53i9), siRNA targeting CPSF4 (si-CPSF4) or a non-specific siRNA (si-ctrl). 373	
Treated cells were then infected with influenza virus H3N2 at a MOI of 4. Supernatants were 374	
harvested at 24 hpi to monitor IFNα and IFNβ levels (Fig. 6A), while the siRNA efficiency was 375	
controlled by western blot on cell lysates (Fig. 6C). 376	
First, our results indicated that the knockdown of all p53 isoforms (including full-length p53α) 377	
strongly reduced the production of IFN-I compared with cells treated with si-ctrl, with more 378	
than a 50% and 40% reduction of IFNα and IFNβ, respectively (Fig. 6A). This result concurred 379	
with previous reports and underlined the contribution of TP53 to the regulation of IFN mediated 380	
antiviral response (51). Interestingly, we observed a very similar impact on IFN production in 381	
the si-P53i9-treated condition, with around 50% reduction of IFNα and IFNβ (Fig. 6A). More 382	
importantly, since the reduction of IFN was similar using either si-P53tot or si-P53i9, it 383	
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suggested that the spliced b and g mRNA variants are the major, if not the only, component of 384	
the global p53-mediated regulation of the IFN response. Regarding CPFS4, a significant 50% 385	
reduction of IFNa and IFNb was observed in si-CPSF4-treated cells compared with si-ctrl-386	
treated cells, suggesting that CPSF4 is also an important player, by itself, in the regulation of 387	
IFN-I production. Furthermore, the combination of si-P53i9 and si-CPSF4 treatments also 388	
decreased the level of IFN production; however, the reduction of IFN was in a range similar to 389	
that seen with single siRNA treatments, without any cumulative effect. These observations were 390	
also supported by western blot, using the phosphorylation of signal transducer and activator of 391	
transcription 1 (STAT1) as an indicator of IFN response (Fig. 6C). These data suggest that both 392	
the spliced p53β and p53γ isoforms and CPSF4 are involved in promotion of IFN-I production 393	
in response to IAV infection, certainly through a common pathway. 394	
To determine whether the CPSF4- and spliced p53 isoform-induced IFN production also occurs 395	
in an extracellular stress context, distinct from IAV infection, we performed similar 396	
experiments whereby we measured the response of siRNA-treated cells exposed to poly(I:C) 397	
treatment, which mimics non-specific viral signaling through Toll-like receptor 3 (TLR3) (Fig. 398	
6B, D). Interestingly, we obtained similar results to that seen with IAV infection using the range 399	
of siRNA-treatment, but only in the context of IFNα. Indeed, compared with si-ctrl-treated cells, 400	
only a limited but statistically significant reduction of IFNβ was achieved in si-P53tot-treated 401	
cells (Fig. 6B). These data suggest that both CPSF4- and spliced p53 isoforms-induced IFN 402	
production is specifically dependent upon IAV infection. 403	
Altogether, these results clearly indicate that spliced p53β and p53γ isoforms are major 404	
contributor to the global p53-mediated regulation of type I IFN. Interestingly, our data suggest 405	
that CPSF4/spliced p53 isoforms are part of the same pathway, stimulating type I IFN 406	
production during IAV infection.  407	
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Discussion  408	
 409	
During their replication cycle, IAV are known to “hijack” the host splicing machinery to 410	
process their smallest gene segments (M and NS). To do this, they have developed accurate 411	
regulation mechanisms to appropriate the host spliceosome to enable the expression of specific 412	
spliced IAV products throughout infection (5). Indeed, several genome-wide screening studies, 413	
dedicated to pinpointing important host factors for IAV replication, have highlighted a large 414	
number of cellular proteins involved in RNA maturation and splicing processes, including 415	
several splicing factors (5, 52-54). However, the impact of IAV infection on the regulation of 416	
splicing of host mRNA has not yet been extensively investigated. 417	
The transcription factor p53, also named “guardian of the genome” or “cellular gatekeeper”, is 418	
most of the time – if not always – targeted by viruses during the time-course of infection (34, 419	
55). This feature is a powerful way for viruses to modulate or hijack p53-mediated cellular 420	
functions, including those involved in the regulation of the immune and inflammatory responses 421	
(33, 39). In the context of IAV, we and others have demonstrated that IAV target p53 at several 422	
transcriptional and post-transcriptional regulatory levels (36-38, 40-42). Among these, we 423	
demonstrated a functional interplay between IAV viral production and p53 isoforms, notably 424	
the p53b isoform, known to be generated by partial retention of TP53-i9 (38, 56). Here, we 425	
describe another layer of interplay, showing that IAV infection modulates the alternative 426	
splicing of TP53 at the level in intron 9, in favor of under-represented spliced forms such as 427	
p53b, which concurs with that previously observed (38). Interestingly, the non-structural 428	
protein NS1 appears to be a major player in this mechanism, as experiments involving transient 429	
NS1 expression recapitulated our initial observation on TP53 splicing in the context of infection 430	
(Fig. 1C). Among the multiple functions of NS1, we currently know that NS1 interferes with 431	
several cellular signaling pathways, including p53, but also has an important role in the 432	
modulation of mRNA maturation and splicing (6, 7), and our results illustrate well how these 433	
different functions overlap during infection. 434	
One striking result in our study was that the CPSF4-binding domain of NS1 is involved in the 435	
NS1-mediated modulation of TP53-i9 retention, as demonstrated by transient expression 436	
experiments (Fig. 1 and 4) and the use of NS1 recombinant viruses (Fig. 2). In addition, our 437	
results suggest a regulatory loop between IAV NS1, and host factors CPSF4/p53 during IAV 438	
infection (Fig. 5-7). Interestingly, a large part of literature dedicated to CPSF4, originates from 439	
studies performed in the context of IAV infection (21). The first described role of CPSF4 is to 440	
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participate to maturation and polyadenylation of cellular pre-mRNA. The binding of NS1 to 441	
CPSF4 inhibited these activities, contributing to the NS1-mediated regulation of host gene 442	
expression and inhibition of the type I IFN response (24, 25, 27, 57). In line with these features, 443	
our results indicate that CPSF4 contributes to the p53-mediated type I IFN response to IAV 444	
infection (Fig. 6), supporting the hypothesis of a link between CPSF4 and the innate immune 445	
response. More recently, several reports have investigated the functional contribution of CPSF4 446	
to the spliceosome machinery, acting as a cofactor for splicing regulators, such as RBFOX2 or 447	
HNRNPA1, suggesting that CPSF4 is more directly involved in the regulation of alternative 448	
splicing (28-30). Once again, our results are in good agreement with this emerging role for 449	
CPSF4. Indeed, we demonstrated that CPSF4 is involved in the regulation of TP53 splicing, 450	
showing that the use of a specific si-RNA targeting CPSF4 contributes to the exclusion of TP53-451	
i9 in favor of the expression of p53α variant, even in basal conditions, outside of an IAV 452	
infection context (Supplementary Fig. 2). Thus, we identified a novel splicing regulator of the 453	
TP53 alternative splicing at the level of its intron 9. Future investigations will be necessary to 454	
understand whether this CPSF4-mediated modulation of splicing is specific to TP53 (or to a 455	
subset of host genes) or rather results from a more global impact on host splicing. 456	
Altogether, our combination of different experimental approaches revealed strong regulatory 457	
connections between NS1, CPSF4 and p53. To make a complete picture of this virus–host trio, 458	
we focused on TP53 splicing and p53 transcriptional activity. First, we demonstrated that 459	
CPSF4 modulates both TP53 splicing and p53 transcriptional activity (Supplementary Fig. 2). 460	
These two events are likely directly correlated, as we previously demonstrated that p53 spliced 461	
isoforms regulate p53 transcriptional activity (45, 46). In parallel, we also demonstrated that 462	
NS1 modulates the alternative splicing of TP53-i9, in favor of p53β and p53γ isoforms, and 463	
that the CPSF4 binding domain of NS1 was involved in this modulation (Fig. 1). This NS1-464	
mediated modulation of TP53 splicing was correlated with a modulation of p53 transcriptional 465	
activity, the latter being in agreement with previously published works (37, 42). In addition, 466	
several studies, including ours, performed in different physiological and pathological contexts, 467	
clearly indicate that alteration or disruption of the splicing machinery have a marked effect on 468	
p53 transcriptional activity and p53-mediated cellular responses in a promoter-dependent 469	
manner, suggesting a role for p53 spliced isoforms in these processes (47, 58). Our results 470	
obtained in the case of IAV infection, or in the experimental contexts of NS1 transient 471	
expression/silencing of CPSF4, confirmed these observations, as we described a marked 472	
deregulation of TP53 splicing associated to a modulation of p53 transcriptional activity in a 473	
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promoter dependent-manner (Figs. 1-3). 474	
Finally, our results focused on viral production and p53-mediated regulation of IFN-I to 475	
complete our understanding of the underlying biological significance of the NS1/CPSF4/p53 476	
interplay. Using specific si-RNAs, we first demonstrated that p53β and p53γ isoforms have a 477	
pro-viral effect (Fig. 4), in line with our previous study (38). In parallel, we have also observed 478	
that silencing of CPSF4, which modulates TP53 splicing, significantly affects viral production 479	
in a p53-dependent manner (Fig. 5). This latter experimental silencing of CPSF4 is comparable 480	
to the early stages of IAV infection, in which NS1 hampers CPSF4 functions. We hypothesize 481	
that the role of CPFS4 in IAV infection may not only rely on the maturation of host pre-mRNA 482	
(21-23) but also on the modulation of TP53 splicing and p53-mediated responses by NS1. 483	
Indeed, little is known about the impact of NS1 on the CPSF complex at the level of splicing 484	
regulation. Our hypothesis is that NS1, via its binding with CPSF4, alters the CPSF complex 485	
and consecutively modify its recruitment as cofactor for splicing regulators. In addition, a 486	
converging point between known functions of CPSF4 and those of p53 is the regulation of IFN-487	
I responses. Indeed, CPSF4 is involved in the NS1-dependent regulation of several host genes 488	
and particularly to the inhibition of the IFN-I response (24-27). In addition, p53 is known to 489	
constitute an amplification loop in the innate immune response, TP53 being part of the family 490	
of IFN-stimulated genes (ISGs), and p53 regulates the expression of several genes involved in 491	
IFN-I response (reviewed in (33)). Our results confirmed these observations (Fig. 6) and 492	
suggested that spliced p53β and p53γ isoforms are major contributor to the global p53-mediated 493	
regulation of type I IFN, and that CPSF4 might be involved in the same regulatory loop.  494	
On the basis of our results, we can propose the following model (depicted in Fig. 7). During 495	
IAV infection, NS1 inhibits p53 transcriptional activity via its interaction with p53, but also via 496	
the modulation of TP53 splicing by “buffering” the function of CPSF4 in mRNA maturation 497	
and splicing (Fig. 7). As a consequence, the spliced p53 isoform modulation of p53 498	
transcriptional activity, and notably p53-mediated antiviral responses, coupled to the cellular 499	
impact of CPSF4 blockade, positively influence viral production. When NS1 is mutated, 500	
preventing its binding to CPSF4, this regulation loop is impaired, and the antiviral response is 501	
increased, limiting viral production (Fig. 7). In future studies, it will be interesting to investigate 502	
the presence of naturally occurring mutations in NS1 of IAV circulating strains that could 503	
interfere in this NS1/CPSF4/p53 trio, to evaluate a possible impact on strain pathogenesis and 504	
virulence. 505	
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In conclusion, our results have aided understanding of the complex mechanisms IAV hijacking 506	
of the host p53 pathway during infection, but they have also highlighted a particular virus–host 507	
trio NS1/CPSF4/p53 that is crucial for viral replication via mRNA maturation and splicing and 508	
p53-mediated antiviral responses. 	509	
	  510	
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Methods 511	
	512	
Cells lines, influenza viruses and infection 513	
Human lung epithelial A549 (wild-type p53; ATCC CCL-185) and H1299 (p53 null; ATCC 514	
CRL-5803) cells were maintained at 37°C in Dulbecco’s modified Eagle’s medium (DMEM; 515	
Life Technologies) supplemented with 10% (or 5% for H1299 cells) of heat-inactivated fetal 516	
calf serum (Dutscher), 2 mM L-glutamine (Sigma Aldrich), penicillin (100 U/mL) and 517	
streptomycin (100 µg/mL) (Lonza), under a 5% CO2 atmosphere.  518	
Influenza viruses A/Moscow/10/99 (H3N2) and A/Puerto Rico/8/34 (H1N1), obtained from the 519	
French national influenza monitoring network GROG (Groupes Régionaux d’Observation de 520	
la Grippe, Lyon, France), were produced in Madin-Darby canine kidney (MDCK) cells (ATCC 521	
CCL-34) in Eagle’s minimum essential medium (EMEM; Life Technologies). Viruses were 522	
titrated on confluent layers of MDCK cells in 96-well plates to determine the 50% tissue culture 523	
infectious dose by endpoint titration (TCID50/mL), which was determined using the Reed and 524	
Muench statistical method (59). A549 and H1299 cells were infected at a multiplicity of 525	
infection (MOI) of 0.1 or 4 TCID50/cell. After 1 h of viral adsorption, cells were overlaid with 526	
DMEM supplemented of 2 mM L-glutamine, penicillin (100 U/mL), streptomycin (100 µg/mL) 527	
and 0.5 µg/mL TPCK-trypsin (Roche diagnostics) and incubated at 37°C.  528	
For viral growth kinetic assays, MDCK cells were infected at MOI of 10-1 or 10-2 TCID50/cell. 529	
After a 1 h viral adsorption period, cells were overlaid with Eagle's minimum elementary 530	
medium (EMEM, Lonza) supplemented with 1 µg/ml trypsin (Roche diagnostics) and further 531	
incubated at 34 °C. Harvested supernatants were centrifuged at 1500g for 10 min and stored at 532	
− 80 °C until analysis. 533	
 534	
Plasmids and TP53-i9 minigene 535	
For transient expression of NS1, A549 and H1299 cells at 40% of confluence were transfected 536	
using TransIT-LT1 Reagent (Mirus), following manufacturer’s instructions, with a panel of pCI 537	
plasmids empty or carrying wild-type or mutated NS1 sequences derived from the H3N2 strain. 538	
Wild-type pCI-NS1 (NS1 wt) was a kind gift from Dr Nadia Naffakh, Institut Pasteur, France. 539	
Three pCI-NS1 mutants (NS1-Y89F, NS1-R38A/K41A and NS1-CPSF4b, mutated from amino 540	
acids 184 to 188, sequence RFLRY in place of GLEWN) were obtained by site-directed 541	
mutagenesis. Each plasmid was validated by sequencing.  542	
For the TP53 splicing assay, the pcDNA3-ASAi9 p53 minigene plasmid (named TP53-i9 543	
minigene) was used, the design and protocol of which were previously described (47). The 544	
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pcDNA3-ASAi9 p53 minigene contains a portion of the TP53 gene that includes the 3′ end of 545	
exon 9, the entire intron 9 and the beginning of exon 10, as pictured in Fig. 1A, as well as the 546	
neomycin-resistant gene used to assess transfection efficiency. In infection experiments, cells 547	
were infected as described, 24-48 h after TP53-i9 minigene transfection. In co-transfection 548	
experiments, the TP53-i9 minigene was transfected simultaneously with indicated quantities of 549	
the pCI-NS1 wt-expressing plasmid.  550	
 551	
RNA analysis and real-time quantitative PCR  552	
Cells lysates were harvested at 8 hours post-infection (hpi; MOI of 4) or at 24 hpi (MOI of 0.1) 553	
and total RNA was extracted using the RNeasy minikit (Qiagen), according to supplier protocol. 554	
Reverse transcription was performed on 1µg of total RNA with SuperScriptII Reverse 555	
Transcriptase (Invitrogen) at 42°C followed by a quantitative PCR using SYBR Green qPCR 556	
Master Mix (Agilent, Santa Clara, CA, USA). In the TP53-i9 minigene experiment, specific 557	
primers for each p53 spliced RNA or neomycin-resistance gene were used, as previously 558	
described (47). For quantitation of endogenous p53 mRNA levels, qPCR was carried out using 559	
TaqMan 2X Universal PCR Master Mix No AmpErase UNG (Applied Biosystem, Carlsbad, 560	
CA, USA) with specific sets of primers and probes: E8/9 primers for amplification of total p53 561	
isoforms, p53β primers for amplification of β forms and Actin primers for normalization, as 562	
previously described (47). The use of actin as a normalisation control was validated in control 563	
experiments, indicating that IAV infection and/or si-CPSF4 did not affect actin CT by RTqPCR. 564	
A complete list of primers and probes used in this study is available in Supplementary Table 565	
1. The ΔΔCT method was used to determine the fold change of mRNA levels using neomycin-566	
resistance or actin expression level as a reference. Relative mRNA levels were quantified in 567	
triplicate, in at least three independent experiments, to perform statistical analyses. The 568	
proportion of β+γ mRNA variants on total expression was measured dividing the sum of β and 569	
γ relative quantities, by the sum of α, β and γ quantities, all forms being individually normalized 570	
against neomycin. This proportion of β+γ variants is used an indicator of the extent of splicing 571	
for comparison purposes. 572	
 573	
Western blotting 574	
Total protein was extracted by scraping and syringing cells in 1X NuPAGE LDS buffer 575	
(Invitrogen). Approximately 15-30 µg of protein were loaded on 10 or 12% SDS gels and 576	
analyzed by immunoblotting using the following antibodies: sheep polyclonal antibody anti-577	
total p53 isoforms (SAPU, Dundee, UK); rabbit polyclonal antibodies anti-NS1 (30F/31F, kind 578	
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gift of Daniel Marc, INRA Tours, France), anti-NP (CDC/IVPS, 30AUG01) and anti-579	
phosphorylated (Tyr701) STAT1 (#9167, Cell Signaling Technology); mouse monoclonal 580	
antibodies anti-p53 TA isoforms (DO-1, Dundee, UK), anti-NS1 (SantaCruz, sc-130568), anti-581	
CPSF4 antibody (Santa-Cruz sc-393316), anti-STAT1 (#9176, Cell Signaling Technology) and 582	
anti-Ku80 (AbCam), which was used as loading control.  583	
 584	
Transactivation assay  585	
A549 cells were transfected with 1 µg of firefly luciferase reporter vectors corresponding to 586	
different p53-responsive elements. Cells were co-transfected with empty or NS1-expressing 587	
pCI plasmids and harvested at 48 hpi. Transfection efficiency was normalized using 100 ng of 588	
Renilla luciferase plasmid. Luciferase activity was measured in whole cell extracts, in triplicate 589	
in two independent experiments, using the Dual-Luciferase Reporter Assay System (Promega), 590	
according to the manufacturer’s instructions. The different reporter vectors used were pG13-591	
Luc with the luciferase gene under the control of thirteen copies of the p53-binding consensus 592	
sequence (5′- CCAGGCAAGTCCAGGCAGG- 3′) and p21-Luc, Mdm2-Luc and Bax-Luc with 593	
the luciferase gene under the control of the complete (p21) or partial (Mdm2 and Bax) promoter 594	
sequence of the corresponding genes (60-62).  595	
 596	
Recombinant viruses 597	
Recombinant PR8/NS1 wt and PR8/NS1-CPSF4b viruses were generated by reverse genetics 598	
approaches, as previously described (63). Briefly, a pHW2000 plasmid containing NS sequence 599	
from H3N2 (49) was mutated to generate a NS1-CPSF4b mutant (from amino acid 184 to 188, 600	
sequence RFLRY in place of GLEWN). Recombinant virus generation was performed by 601	
transfection of 293T cells (ATCC CRL-3216) using set of pHW2000 plasmids from PR8 602	
system and pHW2000 plasmid containing NS wt or NS1-CPSF4b sequences from H3N2 603	
coding. At 48 hpi, viruses in the culture supernatant were harvested and used to infect a layer 604	
of MDCK cells. Viral stocks were prepared after three passages on MDCK cells, and titers were 605	
measured using standard TCID50 methods. Full genomes of recombinant viruses were 606	
validated by sequencing.  607	
 608	
si-RNA treatment 609	
A549 or H1299 cells (cell confluence, 50%), seeded in antibiotic-free medium, were transfected 610	
twice at 24 h intervals with either 50 nM of nonspecific si-RNA (si-ctrl, catalog number 0R-611	
0030-Neg05; Eurogentec), or a pool of si-RNA CPSF4 (on-Target plus Human CPSF4 #10898 612	
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siRNA smartpool, Dharmacon), specific si-RNAs targeting global p53 isoforms (si-P53tot) or 613	
spliced p53β and p53γ isoforms (siP53-i9, Fig. 5A; Eurogentec based on sequences in (47)), 614	
using Oligofectamine (Life Technologies) according to the manufacturer’s instructions. Cells 615	
were then infected or treated 24 h after the last si-RNA transfection. The efficiency of si-RNA 616	
mediated knockdown after treatment was evaluated by RT-qPCR and/or western blotting. 617	
 618	
IFN-α/β ELISA 619	
Twenty-four hours after si-RNAs transfection, A549 cells were infected with H3N2 at MOI of 620	
4 or alternatively treated with 50 µg/mL of extracellular poly (I:C) (Sigma Aldrich). Forty-eight 621	
hours after transfection, IFN-α and IFN-β levels were quantified in supernatants using the 622	
VeriKine Human Interferon Alpha Multi-Subtype Serum ELISA Kit or the VeriKine-HSTM 623	
Human Interferon Beta Serum ELISA kit (PBL Assay Science, NJ, USA), respectively, 624	
following the manufacturer’s protocol.  625	
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Figures captions 798	
 799	
Figure 1 – Influenza viruses and the viral NS1 protein alone modulate TP53-i9 minigene 800	
alternative splicing. (A) Schematic of the TP53-i9 minigene. Intron 9 of p53 was inserted into 801	
pCDNA3 plasmids with part of exon 9 and 10 on both sides, transcription of mRNA 802	
corresponding to each spliced variants was under control of the CMV promoter (47). (B) Levels 803	
of mRNA corresponding to p53 spliced variants α, β and γ were measured in H1299 cells (p53 804	
null) in which the TP53-i9 minigene plasmid was transfected 36 hours before mock infection 805	
or infections by H1N1 or H3N2 influenza viruses. Cells lysates were harvested at 8 hpi for 806	
infection at MOI of 4 or at 24 hpi for infection at MOI of 0.1, and relative levels of mRNA 807	
corresponding to α, β and γ p53 spliced variants were measured by specific RT-qPCR. mRNA 808	
level of each variant was normalized against the neomycin-resistance gene, which is also 809	
encoded by the TP53-i9 minigene. Viral protein expression (NP and NS1) was monitored by 810	
western blot. (C) The relative spliced mRNA level of p53α, p53β and p53γ isoforms was 811	
measured in H1299 cells 48 h after co-transfection of TP53-i9 minigene and 1µg of an empty 812	
pCI plasmid or a plasmid containing wt NS1 (pCI NS1 wt, from influenza strain 813	
A/Moscow/10/99 (H3N2)) and was used to calculate the proportion of β+γ isoforms out of the 814	
total α, β and γ variant p53 mRNA expression. Mean values +/- standard deviation for at least 815	
three independent experiments are shown, and statistical tests compared each condition with its 816	
control condition using two-way ANOVA (**, p < 0.01; ***, p < 0.001). (D, E) In H1299 cells, 817	
the TP53-i9 minigene was co-transfected with 1µg of empty pCI, pCI NS1wt (results extracted 818	
from Figure 1C) or pCI NS1-Y89F, pCI NS1-R38A/K41A and pCI NS1-CPSF4b mutants (D) 819	
or with increasing amounts (0.1, 0.5 or 1µg) of pCI NS1 wt or pCI NS1-CPSF4b plasmid (E). 820	
Forty-eight hours after co-transfection, levels of α, β and γ variant mRNA were measured 821	
(Supplementary figure 1) and used to estimate the β+γ proportion. Efficacy of NS1 transient 822	
expressions was validated by western blot. Mean values +/- standard deviation from more than 823	
three independent experiments are shown, and statistical tests compared each condition with its 824	
control empty condition or NS1 wt condition using Student’s t-test (*, p < 0,05; **, p < 0.01 825	
and ***, p < 0.001). 826	
 827	
Figure 2 – IAV-regulated p53 expression is affected by mutant NS1 CPSF4-binding 828	
mutant. A. Comparative viral kinetics between recombinant IAV PR8/NS1 wt or PR8/NS1-829	
CPSF4b viruses. A549 cells were infected with the two viruses at MOI of 0.01 and supernatants 830	
were harvested at 24, 48, 72 and 96hpi for determination of viral titers. B-E. A549 cells were 831	
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mock-infected or infected with either recombinant IAV PR8/NS1 wt or PR8/NS1-CPSF4b 832	
viruses. Cells lysates were harvested at 8 hpi (MOI of 4, B, C) or 24 hpi (MOI of 0.1, D, E). 833	
Detection of total p53 and p53β isoforms was performed by RT-qPCR and western blot (SAPU 834	
antibody). Viral proteins NP and NS1 were also detected. # and ## indicate short and long 835	
exposure, respectively. Mean values +/- standard deviation of experimental duplicates are 836	
shown and statistical tests compared each condition with its control condition using two-way 837	
ANOVA and Dunnett’s post-test (*, p < 0.05; **, p < 0.01 and ***, p < 0.001). 838	
 839	
Figure 3 – The CPSF4-binding domain of NS1 protein plays a crucial role in the alteration 840	
of p53 isoforms expression and p53 transcriptional activity. A549 cells were transfected 841	
with pG13-Luc, Mdm2-Luc, Bax-Luc or p21-Luc reporter plasmids together with increasing 842	
concentrations of an NS1 expressing plasmid (either H3N2 NS1 wt or H3N2 NS1-CPSF4b 843	
mutant). p53 transactivation activity was measured after 48h, in triplicate on two independent 844	
experiments and expressed in relative luciferase units (RLU) compared with the empty plasmid 845	
condition. Mean values +/- standard deviation are shown and statistical tests compared each 846	
condition with the empty plasmid condition using one-way ANOVA and Dunnett’s post-test 847	
(*, p < 0.05; **, p < 0.01 and ***, p < 0.001). 848	
 849	
Figure 4 – Silencing of the TP53-i9 alternatively spliced β and γ isoforms impairs IAV 850	
replication. A549 cells were treated twice with either the control non-specific si-RNA (si-ctrl) 851	
or a specific si-RNA targeting the p53β and p53γ spliced isoforms, as illustrated in (A). Twenty-852	
four hours after the last si-RNA treatment, cells were infected with H3N2 virus at MOI of 0.1 853	
or 0.01. Supernatants were harvested at 24 h intervals over 3 days, and the viral replication was 854	
determined by endpoint TCID50 titration in MDCK cells (measured in quadruplicate in two 855	
independent experiments) (B). Cells lysates were harvested before infection (T=0) or at 72 hpi 856	
to quantify p53total and p53β mRNA expression levels by RT-qPCR, normalized on actin 857	
expression (C). Cellular and viral proteins were detected in western blot (D). # and ## indicate 858	
short and long exposure respectively. Data represent independent experimental duplicates. 859	
Mean values +/- standard deviation are shown, and statistical tests compared each condition 860	
with the si-ctrl T=0 condition using two-way ANOVA (*, p < 0.05; **, p < 0.01). 861	
 862	
Figure 5 – The silencing of CPSF4 impacts IAV replication in a partially p53-dependent 863	
manner. A549 (A-C) or H1299 (D-F) cells were treated twice with either a control nonspecific 864	
siRNA (si-ctrl) or a pool of siRNAs targeting cellular CPSF4. Twenty-four hours after the last 865	
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treatment, cells were infected with H3N2 at MOI of 0.1 or 0.01. Supernatants were harvested 866	
at 24 h intervals over 3 days, and the viral kinetics in A549 cells (A) or H1299 cells (D) were 867	
determined by endpoint TCID50 titration in MDCK cells (measured in quadruplicate in two 868	
independent experiments). Cells lysates were harvested before infection (T=0) or at 72 hpi and 869	
cellular p53 and CPSF4, together with viral NP and NS1 proteins were detected by western blot 870	
(B,E). CPSF4 mRNA expression was also measured by RT-qPCR (normalized against GAPDH 871	
expression) at T=0 and 72 hpi (C,F). All data represent independent experimental duplicates. 872	
Mean values +/- standard deviation are shown, and statistical tests compared each condition 873	
with the si-ctrl at T=0 control using two-way ANOVA (*, p < 0.05; **, p < 0.01 and ***, p < 874	
0.001). 875	
 876	
Figure 6 –p53β and p53γ isoforms together with CPSF4 contribute to p53-mediated IFN-877	
I-response to IAV infection and extracellular stresses. A549 cells were treated twice with 878	
nonspecific si-RNA (si-ctrl), a siRNA targeting all p53 forms (si-P53tot, figure 5A), a specific 879	
siRNA targeting alternatively spliced p53β and p53γ isoforms (si-P53i9, figure 5A), a pool of 880	
si-RNAs targeting CPSF4 (si-CPSF4) or a combination of si-P53i9 and si-CPSF4. Twenty-four 881	
hours later, cells were infected with H3N2 at MOI of 4 (A+C)) or added extracellular poly (I:C) 882	
to induce a stress through TLR3 activation (B+D). (A,B) Supernatants were harvested 24 h after 883	
treatment IFN-α and IFN-β levels were quantified. (C) Cell lysates were also collected to 884	
monitor infection, si-RNA efficiency and type I IFN response via STAT1 phosphorylation by 885	
western blot. # and ## indicate short and long exposure respectively with DO-1 antibody. Mean 886	
values +/- standard deviation of experimental duplicate are shown and two-way ANOVA test 887	
compared each condition with the si-ctrl condition (*, p < 0.05; **, p < 0.01 and ***, p < 0.001). 888	
 889	
Figure 7 – Working model of interplay between IAV NS1 protein, cellular factor CPSF4 890	
and TP53 splicing. During IAV infection, IAV NS1 inhibits p53 transcriptional activity via its 891	
interaction with p53, but also via the modulation of TP53 splicing by “buffering” the function 892	
of CPSF4 in mRNA maturation and splicing. As a result, the spliced p53 isoform modulation 893	
of p53 transcriptional activity, and notably p53-mediated antiviral responses, coupled to the 894	
cellular impact of CPSF4 blockade, positively influence viral production. When NS1 is 895	
mutated, preventing its binding to CPSF4, this regulation loop is impaired, and the antiviral 896	
response is increased, limiting viral production. 897	
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Supplementary Figure 1. (A,B) The expression of α, β and γ mRNA variants was measured 
by RT-qPCR in H1299 cells 48 h after co-transfection of TP53-i9 minigene and 1µg of the 
empty pCI plasmid, pCI NS1wt, pCI NS1-Y89F, pCI NS1-R38A/K41A or pCI NS1-CPSF4b 
plasmids (A) or with increasing amounts (0.1, 0.5 or 1µg) of pCI NS1 wt or pCI NS1-CPSF4b 
plasmids (B). Mean values +/- standard deviation for at least three independent experiments are 
shown, and statistical tests compared each condition with its control condition using two-way 
ANOVA (**, p < 0.01; ***, p < 0.001). (C) A549 cells were transfected with 1µg of the empty 
pCI plasmid, pCI NS1 wt or pCI NS1-CPSF4b for 48 h, and endogenous expression of total 
p53 or β mRNA variants were measured by RT-qPCR. Levels of mRNA were measured in five 
independent experiments and normalized against the empty plasmid condition. (D) Increasing 
concentrations of NS1-expressing plasmids (wt or NS1-CPSF4b mutant) were transfected into 
A549 cells, and p53 isoform expression was detected by western blot using SAPU antibody. # 
and ## indicate short and long exposure respectively. Based on their size, we identified some 
p53 isoforms. NS1 was also detected, and Ku80 was used as loading control. 
 
 
 
Supplementary Figure 2 – The silencing of cellular CPSF4 factor impacts TP53 splicing 
and p53 transcriptional activity. CPSF4 silencing was performed by transfecting H1299 
(p53-null) or A549 (p53wt) cells with either a non-specific siRNA (negative-control si-ctrl), or 
a pool of siRNAs targeting cellular CPSF4. (A) Twenty-four hours following siRNA treatment, 
H1299 cells were transfected with the TP53-i9 minigene plasmid, and the relative expression 
of spliced α, β and γ p53 mRNA variants was measured by RT-qPCR at 48 hours post 
transfection. (B) Similar si-RNA treatment was performed on A549 cells, and relative mRNA 
levels of global p53 or β variants was measured and normalized on actin expression. (C) 
Twenty-four hours following siRNA treatment, A549 cells were transfected with pG13-Luc, 
Mdm2-Luc, Bax-Luc or p21-Luc reporter plasmids and relative luciferase units were measured 
48 h later. Mean values +/- standard deviation of experimental duplicates are shown and 
statistical tests compared each condition with the si-ctrl condition using two-way ANOVA and 
Dunnett’s post-test (**, p < 0.01). 
 
 
 
Supplementary Figure 3. (A) After being treated with siRNA targeting alternatively spliced 
p53β and p53γ isoforms (si-P53i9), cell lysates were harvested before (T=0) and after infection 
with H3N2 influenza, CPSF4 expression levels were quantified by RT-qPCR and normalized 
against GAPDH expression. The relative level of protein (RPL) for CPSF4 was measured by 
densitometry from western blots of Figure 5F (B), Figure 6B (C) and Figure 6E (D).  
	
